Direct Labeling of Gold Nanoparticles with Iodine-131 for Tumor Radionuclide Therapy
Meilin Zhu,Lingzhou Zhao,Xia Lu
DOI: https://doi.org/10.2147/ijn.s484976
IF: 7.033
2024-11-16
International Journal of Nanomedicine
Abstract:Meilin Zhu, 1 Lingzhou Zhao, 2 Xia Lu 2 1 School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China; 2 Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China Correspondence: Xia Lu, Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China, Tel +86 18051061486, Email Purpose: Gold nanoparticles (Au NPs) are widely used as versatile templates to develop multifunctional nanosystems for disease diagnosis and treatment. Iodine can bind to gold via chemisorption, making this a simple method for labeling Au NPs with radioactive iodine. However, the evaluation of tumor radionuclide therapy is insufficient. In this study, we investigated the feasibility of 131 I-adsorbed Au NPs as novel nanoprobes for tumor radionuclide therapy. Materials and Methods: Radiolabeling was performed by mixing Au NPs and 131 I, and the radiochemical purity (RCP) and in vitro stability of 131 I-adsorbed Au NPs were analyzed under different conditions, including various temperatures, pH values, and 131 I concentrations. The tumor accumulation and therapeutic potential of 131 I-adsorbed Au NPs were assessed using a subcutaneous tumor model after intratumoral injection. Results: The data showed that the chemisorption of the Au NPs onto 131 I was instant, specific, and quantitative. The 131 I-adsorbed Au NPs exhibited high in vitro stability in different media, distinct inhibitory effects on tumor cells in vitro, good retention ability, and therapeutic effects after intratumoral injection into tumor-bearing mice in vivo. Conclusion: Our work demonstrates that chemisorption of Au NPs and radioiodine has great potential as a strategy for constructing various nanosystems for theranostic applications. Keywords: gold nanoparticles, iodine-131, chemisorption, radionuclide therapy Radionuclide therapy delivers cytotoxic levels of radiation to specific disease sites and has been widely applied in cancer treatment. 1,2 Unlike conventional radiation therapy, which targets tumors externally, radionuclide therapy uses therapeutic radiopharmaceuticals that specifically bind to tumor tissues at the cellular level, exerting ionizing radiation within tumor cells, causing double-strand DNA damage, and eventually leading to tumor apoptosis. 3,4 Therapeutic radiopharmaceuticals are composed of appropriate radionuclides and tumor target-specific moieties, including antibodies, peptides, and small molecules. 5 Although numerous therapeutic radionuclides have been developed for radionuclide therapy, including but not limited to iodine-125 ( 125 I), iodine-131 ( 131 I), rhenium-188 ( 188 Re), yttrium-90 ( 90 Y), lutetium-177 ( 177 Lu), astatine-211 ( 211 At) and radium-223 ( 223 Ra), 131 I is one of the most widely used therapies in clinical application due to its favorable physical properties, safety, and low cost. 6,7 Advances in cancer nanomedicine have accelerated the use of various nanoparticles (NPs) as versatile carriers for the development of therapeutic radiopharmaceuticals. 8–11 In particular, gold NPs (Au NPs) have emerged as attractive nanoplatforms for tumor radionuclide therapy because of their remarkable physicochemical properties. 12,13 Through facile surface modifications, Au NPs can be synchronously functionalized with targeting ligands and therapeutic radionuclides for superior cancer therapy, which improves tumor uptake and minimizes unnecessary radiation exposure to normal tissues. 14 Meanwhile, the β-particles emitted from radionuclides, such as 131 I, can be converted to X-rays via the Bremsstrahlung reaction; these X-rays have a much greater penetration depth than the emitted β-particles, which further strengthen the anti-tumor efficacy. 6,15,16 Therefore, radiolabeled Au NPs possessing synergistic effects in tumor treatment have attracted much interest. To date, we and several other groups have reported different forms of 131 I-labeled Au NPs as therapeutic radiopharmaceuticals for tumor therapy via intravenous or intratumoral injection. 17–20 For 131 I radiolabeling of Au NPs, certain functional groups are generally essential, such as tyrosine residues, which require appropriate modifications before radiolabeling. Although these modified Au NPs can be effectively labeled with 131< -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology